SCHEMBL6442933

SCHEMBL6442933

Cc1cnc(COc2nc(N)nc(-n3cccn3)c2C#N)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.42
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
NLRP3 Q96P20 2/20 0.34
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GRM5 P41594 3/20 0.33
POLB P06746 1/20 0.32
SQOR Q9Y6N5 2/20 0.32
LCK P06239 1/20 0.31
KIT P10721 1/20 0.31
SRC P12931 1/20 0.31
KDR P35968 1/20 0.31
KCNH2 Q12809 1/20 0.30
TLR7 Q9NYK1 1/20 0.30
ALDH1A1 P00352 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441301 0.86 ADORA2A (0.44) ADORA2ANLRP3GABRA1GABRG2GABRB3
SCHEMBL6441674 0.83 ADORA2A (0.46) ADORA2ANLRP3GABRA1GABRG2GABRB3
SCHEMBL6442325 0.82 NLRP3 (0.42) ADORA2AHSP90AA1HSP90AB1NLRP3GRM5
SCHEMBL6444568 0.77 ADORA2A (0.43) ADORA2ANLRP3GRM5SQORTLR7
SCHEMBL6442519 0.77 MGMT (0.46) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6441693 0.76 ADORA2A (0.46) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6467274 0.76 ADORA2A (0.44) ADORA2ASQORADORA1NPC1RAB9A
SCHEMBL6444357 0.75 SQOR (0.37) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL5131946 0.72 ADORA2A (0.48) ADORA2APOLBALDH1A1HPGDKDM4E
SCHEMBL6441954 0.71 ADORA2A (0.46) ADORA2AGABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885HSP90AA1 1714/4885HSP90AB1 1866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.